Table 2.
NK cell–related bladder cancer clinical trials.
| Drug | Target | Clinical Setting | Phase | Trial ID |
|---|---|---|---|---|
| UGN-201 | TLR7 | NMIBC/MIBC undergoing cystectomy | Phase I | NCT05055050 |
| N-803 | IL15 | NMIBC | Phase Ib/IIb | NCT02138734 |
| N-803 | IL15 | BCG unresponsive NMIBC | Phase II/III | NCT03022825 |
| EG-70 | IL2/RIG-I | BCG unresponsive NMIBC | Phase I/II | NCT04752722 |
| SEA-TGT | TIGIT | Refractory/metastatic solid tumor | Phase I | NCT02326168 |
| MDNA11 | IL2 | Unresectable/metastatic solid tumor | Phase I/II | NCT05086692 |
| NKTR-214 (± nivolumab) | IL2 | Cisplatin ineligible, locally advanced/metastatic bladder cancer | Phase II | NCT03785925 |
| ST-067 | IL18 | Refractory/progressive solid tumor | Phase I/II | NCT04787042 |
| IK-175 (± nivolumab) | AHR | Refractory, unresectable, progressive disease | Phase I | NCT04200963 |
| S0-C101 (± pembrolizumab) | IL15 | Refractory/metastatic solid tumors | Phase I | NCT04234113 |
| DF1001–001 (± nivolumab or paclitaxel) | NK cell activation | Locally advanced/metastatic solid tumors | Phase I/II | NCT04143711 |
| Lirilumab + nivolumab (vs. nivolumab) | KIR | Cisplatin-ineligible MIBC | Phase Ib | NCT03532451 |
| D-CIK (+ anti-PD-1) | NK cell activation | Refractory advanced solid tumors | Phase I/II | NCT02886897 |
| CIK | NK cell activation | Stage I-III bladder cancer | Phase II | NCT02489890 |
| M7824/M9241 + SBRT | PD-1, TGFβ, IL12 | Advanced or metastatic non-prostate GU cancer | Phase I | NCT04235777 |
Abbreviations: CIK, cytokine-induced killer cells; D-CIK, dendritic cells and cytokine-induced killer cells; RIG-I, retinoic acid-inducible gene I; TIGIT, T cell immunoreceptor with Ig and ITIM domains.